phospho nuclear factor kappa b nf κb p65  (Cell Signaling Technology Inc)

Journal: Inflammation

Article Title: Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation

doi: 10.1007/s10753-025-02446-7

Figure Lengend Snippet: Narciclasine-mediated H3K18la is associated with the activation of the NF-κB pathway in ECs . ( A ) Schematic diagram of histone H3 lysine-18 lactylation (H3K18la) inhibition. ( B - D ) Western blotting analysis of VCAM1 (110 kDa), ICAM1 (90 kDa), and H3K18la (15 kDa) in HUVECs under the following conditions: ( B ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of 2-deoxy-D-glucose (2-DG, 0.5 mM), or sodium lactate (NaLac, 10 mM) for 24 h; ( C ) Transfection with negative control siRNA (siNC), siLDHA, or siP300 for 48 h, followed by stimulation with ox-LDL (100 µg/mL) for 24 h; ( D ) Stimulation with ox-LDL (100 µg/mL) in the presence or absence of dichloroacetate (DCA, 10 mM) for 24 h. Protein band intensities were quantified using ImageJ (version 1.48); H3K18la was normalized to H3 (15 kDa), and VCAM1 and ICAM1 to β-actin (42 kDa). Quantitative data are shown in Supplementary Fig. S14B-D ( n = 3 biological replicates). ( E ) Schematic diagram of H3K18la promotion. ( F - G ) Western blotting analysis of VCAM1 and H3K18la in HUVECs under the following conditions: ( F ) Pretreatment with or without narciclasine (Narc, 20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or sodium acetate (NaAc, 10 mM) for 24 h; ( G ) Pretreatment with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of entinostat (MS275, 0.5 µM) for 24 h. Protein band intensities were quantified using ImageJ, with H3K18la was normalized to H3, VCAM1 to β-actin. Quantitative data are shown in Supplementary Fig. S14E and F ( n = 3 biological replicates). ( H - I ) HUVECs were pretreated with or without 20 nM Narc for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in the presence or absence of 10 mM NaLac for 24 h. ( H ) Representative images of PKH26-labeled THP-1 monocyte adhesion to endothelial cells (scale bar = 250 μm, 10× magnification). The right panel shows the quantification of adherent monocytes from 10 random fields per replicate, expressed as cells per field ( n = 3 biological replicates). ( I ) Representative images of RAW 264.7 macrophage chemotaxis toward HUVEC-conditioned medium (Scale bar = 50 μm, 20× magnification). The right panel shows the quantification of migrated cells from 5 random fields per well, expressed as cells per field ( n = 3 biological replicates). ( J ) Western blotting analysis of p-p65 (65 kDa), and p65 (65 kDa) in HUVECs pretreated with or without Narc (20 nM) for 6 h, followed by stimulation with ox-LDL (100 µg/mL) in combination with either NaLac (10 mM) or MS275 (0.5 µM) for 1 h. Protein band intensities were quantified using ImageJ, with the p-p65/p65 ratio (right panel) calculated after normalizing both p-p65 and total p65 to β-actin ( n = 3 biological replicates). ( K ) Genome browser tracks of CUT&Tag signals for H3K18la at representative target gene loci in HUVECs. The tracks display normalized signal intensity (Reads Per Kilobase per Million mapped reads, RPKM) from a single biological replicate, aligned to the GRCh38/hg38 genome build. ( L ) KEGG pathway analysis of the 1147 genes overlapping between H3K18la-bound genes and genes downregulated by Narc. The Narc-downregulated gene set was defined from RNA-seq data (FDR < 0.05, |fold change| > 1.5; n = 3 biological replicates). The underlying RNA-seq data are available under GEO accession GSE202556 . ( M ) ChIP-qPCR analyses of H3K18la enrichment at the promoters of the indicated genes in HUVECs treated with ox-LDL (100 µg/mL, 24 h) in the presence or absence of Narc (20 nM). Data were normalized to input chromatin and are presented as fold enrichment relative to the IgG control ( n = 4 biological replicates). All data were represented as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparisons test

Article Snippet: Antibody against p-p65 (3031, 1:1,000) was acquired from Cell Signaling Technology, Inc. (MA).

Techniques: Activation Assay, Inhibition, Western Blot, Transfection, Negative Control, Labeling, Chemotaxis Assay, RNA Sequencing, ChIP-qPCR, Control

Journal: World Journal of Gastroenterology

Article Title: Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation

doi: 10.3748/wjg.v32.i2.114057

Figure Lengend Snippet: Cedrol inhibited toll-like receptor 4-mediated mitogen-activated protein kinase and nuclear factor kappa B signaling in vivo and in vitro . A-D: Phosphorylated and total protein abundance of mitogen-activated protein kinase signaling molecules [extracellular regulated protein kinase (ERK)1/2, c-Jun N-terminal kinase (JNK), p38] in colonic tissues of mice ( n = 6); E: Cellular viability was quantified with the cell counting kit-8 method ( n = 3); F-H: Proinflammatory cytokine expression in RAW264.7 macrophages across experimental groups ( n = 3); I-K: Inducible nitric oxide synthase and cyclooxygenase-2 protein expression in RAW264.7 cells across groups ( n = 3); L-P: Phosphorylated and total protein expression of ERK1/2, JNK, p38 and nuclear factor kappa B p65 in RAW264.7 macrophages ( n = 3). Data are expressed as mean ± SD. a P < 0.05. b P < 0.01. c P < 0.001. d P < 0.0001. CE: Cedrol; DSS: Dextran sulfate sodium; ERK: Extracellular regulated protein kinase; p-ERK: Phospho-extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; p-JNK: Phospho-c-Jun N-terminal kinase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; TNF: Tumor necrosis factor; IL: Interleukin; mRNA: Messenger RNA; LPS: Lipopolysaccharide; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

Article Snippet: After blocking in 5% skim milk, membranes were incubated overnight at 4 °C with primary antibodies targeting: Phospho-extracellular regulated protein kinase (ERK) 1/2 (Thr202/Tyr204); ERK1/2; Phospho-c-Jun N-terminal kinase (JNK) (Thr183/Tyr185); JNK; Phospho-p38 (Thr180/Tyr182); P38, phospho-nuclear factor kappa B (NF-κB) p65 (Ser536); NF-κB p65 (Cell Signaling Technology, Daners, MA, United States); Cyclooxygenase-2 (COX-2); Inducible nitric oxide synthase (iNOS); Glyceraldehyde-3-phosphate dehydrogenase (Proteintech, Wuhan, Hubei Province, China).

Techniques: In Vivo, In Vitro, Quantitative Proteomics, Cell Counting, Expressing

Journal: World Journal of Gastroenterology

Article Title: Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation

doi: 10.3748/wjg.v32.i2.114057

Figure Lengend Snippet: Cedrol treated dextran sulfate sodium-induced colitis by inhibiting inflammation, restoring the intestinal barrier, and rebalancing gut microbiota. TNF: Tumor necrosis factor; IL: Interleukin; DSS: Dextran sulfate sodium; LPS: Lipopolysaccharide; MD2: Myeloid differentiation factor 2; TLR4: Toll-like receptor 4; MAPK: Mitogen-activated protein kinase; ERK: Extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; NF-κB: Nuclear factor kappa B; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.

Article Snippet: After blocking in 5% skim milk, membranes were incubated overnight at 4 °C with primary antibodies targeting: Phospho-extracellular regulated protein kinase (ERK) 1/2 (Thr202/Tyr204); ERK1/2; Phospho-c-Jun N-terminal kinase (JNK) (Thr183/Tyr185); JNK; Phospho-p38 (Thr180/Tyr182); P38, phospho-nuclear factor kappa B (NF-κB) p65 (Ser536); NF-κB p65 (Cell Signaling Technology, Daners, MA, United States); Cyclooxygenase-2 (COX-2); Inducible nitric oxide synthase (iNOS); Glyceraldehyde-3-phosphate dehydrogenase (Proteintech, Wuhan, Hubei Province, China).

Techniques: